Industry groups seek changes to FDA guidance on Form 483 responses
Industry groups and legal experts want the US Food and Drug Administration (FDA) to make significant revisions to a proposed guidance on how pharmaceutical manufacturers should address Form 483 observations after a current good manufacturing practice (CGMP) inspection.
The commenters argued that the guidance often doesn’t fully account for the complexities of the responses and are concerned that the consultant and counsel disclosure requirements may make it harder to get outside help.
In March, FDA published the draft guidance on its expectations for responding to Form 483s when a drug facility is found to have not met CGMP expectations. The agency has received several dozen comments from stakeholders in response to the guidance, asking for clarifications and changes intended to ease administrative and other burdens. (RELATED: FDA drafts guidance on best practices for responding to inspection observations, Regulatory Focus 6 March 2026)
PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) generally supported the intent of the draft guidance but said it is concerned that the guidance may be interpreted as an overreach by the agency. The group noted that the draft guidance provides details on the process for investigating manufacturing deviations, some of which appear to exceed current regulatory requirements.
"PhRMA asks FDA to clarify, provide further guidance, or revise its substantive and format and content recommendations to better align with FDA’s authorities under the Federal Food, Drug, and Cosmetic Act (“FD&C Act”) and implementing regulations," said PhRMA.
PhRMA asked FDA to emphasize that FDA 483 responses are voluntary and non-binding. Furthermore, it asked the agency to state that manufacturers may take approaches not listed in the guidance that may still meet regulatory requirements.
"Although the Draft Guidance includes FDA’s standard disclaimer that guidance documents do not establish legally enforceable responsibilities and should be viewed only as recommendations, PhRMA is concerned that FDA compliance officers and facility reviewers may begin to apply the Draft Guidance’s recommendations as new CGMP requirements," the group wrote. "PhRMA appreciates that many of the recommendations in the Draft Guidance reflect common practices that FDA has found beneficial in its review of FDA 483s.
"However, companies should have risk-based discretion and flexibility in how they address deviations and nonconformances encountered during the manufacturing process, so long as the results are compliant with CGMP requirements," the group added.
PhRMA asked FDA to clarify that not all FDA 483 observations are considered CGMP deficiencies or deviations. It also asked the agency to clarify that companies can contest the observations in the Form 483 on regulatory grounds, in addition to scientific and technical grounds.
"The Draft Guidance notes that inspectional observations may be contested on a technical or scientific basis, but does not address how observations may be contested on other grounds, such as disagreements over applicable regulatory requirements," said PhRMA. "An establishment may conclude that the FDA investigator misapplied a regulatory requirement and choose to respond on that ground.
"Were FDA to agree with the establishment’s interpretation, the need to conduct any further CGMP investigation could be obviated," the agency added. "FDA should clarify that avenues available to contest or clarify technical and scientific issues apply equally to disagreements over regulatory requirements."
Additionally, PhRMA asked FDA to ensure its recommendations on management responsibility in the guidance align with existing CGMP regulations, acknowledge that evaluating the effectiveness of a corrective and preventive action plan (CAPA) depends on its scope and complexity, clarify how to respond to situations where a deviation may need more than 15 days to resolve, and ensure its risk assessment recommendations are aligned with its existing authorities. The group said that while it appreciated the agency's adoption of the International Council for Harmonisation (ICH) Q9(R1) guidance’s definition of risk assessment, it asked FDA to emphasize that the principles in the ICH guidance are applicable to the broader risk assessment recommendations of their own guidance.
"Specifically, the Draft Guidance should acknowledge ICH Q9’s recommendation that '[i]t is neither always appropriate nor always necessary to use highly formal quality risk management methods and tools. The use of less formal quality risk management methods and tools can be considered acceptable,'" said PhRMA. "Accordingly, FDA should clarify in the Draft Guidance that the level of detail and formality of risk assessment recommended in the FDA 483 response may vary depending on the underlying risk to product quality, consistent with the approach set forth in ICH Q9(R1)."
PhRMA also asked the agency to clarify that establishments are not required to disclose the identity of consultants or legal counsel they use when responding to Form 483s, and requested that the agency revise parts of the guidance to reduce administrative burdens, clarify that only relevant information in attachments needs to be translated into English, clarify translator qualifications, and clarify certain timelines and follow-up requirements.
AAM
The Association for Accessible Medicines (AAM) expressed concern about certain recommendations in the draft guidance, including disclosures for response preparers and letters of authorization. The group asked for more clarity and transparency regarding the FDA's processes after entities submit responses to Form 483s, since both surveillance inspections and pre-approval/pre-license inspections (PAIs/PLIs) can affect pending marketing applications.
"Recognizing that the processes and staff may differ across inspection types, the guidance should separately describe FDA’s internal review procedures and expected timelines for surveillance inspections and PAIs/PLIs, including how information is shared across the inspection team and application reviewers and when facilities can anticipate receiving the Establishment Inspection Report (EIR)," said AAM. "The guidance should also outline opportunities for communication during the period after issuance of a Form 483 but before inspection classification or an application action (e.g., complete response letter), such as through acknowledgment of receipt, clarification questions, or other mechanisms for dialogue, to support timely resolution of outstanding issues.
"Additionally, the Draft Guidance should address how observations arising from Remote Regulatory Assessments (RRAs) will be communicated and how firms should respond, as this process may differ from traditional onsite inspections," the group added.
Like PhRMA, AAM noted that the draft guidance cites other agency and non-agency guidance documents, including ICH Q10 and ICH Q9(R1). It asked FDA to ensure that cross-referencing to other guidance does not expand the CGMP principles outlined in the draft guidance, and that it does not interpret the cited guidances as revisions to how they should be interpreted.
AAM also asked for clarification about disclosing the identity of the Form 483 response preparer.
"It is important to clarify that 'response preparer' refers to the person or entity principally responsible for drafting or compiling the response as a whole, and does not include individuals who provided comments or technical input on discrete aspects of the response," said AAM. "Where the establishment itself prepares and submits the response, identifying the establishment and signatory should be sufficient absent a need to identify a non-establishment representative who is actually communicating with FDA on the establishment’s behalf.
"This clarification would reduce unnecessary burden while preserving the information FDA may need to understand who is submitting the response," the group added.
AAM asked FDA to remove certain requirements regarding the identification of the response preparer, remove references to outside counsel information, or at least clearly state that such information is voluntary and not intended to override any attorney-client privilege. The group said that establishments have a right to obtain confidential legal advice from both in-house and outside counsel, and are not required to disclose whether outside counsel was involved in advising on, investigating, or contributing to a Form 483 response.
On a similar note, AAM asked FDA to remove any requirement to disclose letters of authorization if the establishment has retained a consultant or external counsel. The group also asked the agency to clarify that an executive summary is recommended for lengthy or multi-observation responses. However, it asked regulators to state that such summaries may be omitted when the response is already clear and concise.
AAM noted that the draft guidance cites a 2018 data integrity guidance and asked FDA to ensure the draft guidance has the same flexibility regarding the use of consultants. The group also emphasized the need for timely responses from the agency regarding scientific disagreements.
"We recommend that FDA state that when a company raises a significant scientific or technical disagreement in a timely Form 483 response and supports that position with relevant data and rationale, FDA should provide an appropriate and timely response through the office directing the inspection or another designated review function," said AAM. "That clarification would promote transparency and could help resolve disputes earlier, potentially narrowing issues before escalation to warning letters or more formal dispute-resolution mechanisms."
Hyman, Phelps & McNamara
The law firm Hyman, Phelps & McNamara also commented on the draft guidance and argued that, given the infrequency of foreign inspections, FDA should verify foreign establishment CAPAs before reinspection. The firm elaborated that if the agency does not verify that CAPAs have been implemented and are effective until reinspection of foreign drug manufacturing establishments, it puts domestic establishments at a disadvantage and creates incentives for them to move abroad.
"Given the emphasis the current administration has placed on domestic manufacturing and the number of initiatives FDA has launched in furtherance of that goal, we assume it is not FDA’s objective to subject foreign facilities to a lesser level of regulatory scrutiny," said Hyman, Phelps & McNamara. "FDA should, at a minimum, consider use of additional oversight tools such as more frequent remote regulatory assessments to conduct inspection activities of foreign establishments including reviewing manufacturing and other quality records, verifying data integrity to inform decisions to take further regulatory action, and verifying corrective actions taken by foreign manufacturing facilities prior to reinspection."
The law firm said the format and content expectations for initial Form 483 responses detailed in the draft guidance fail to account for the complexity of the Form 483s. It argued that some investigations can't be completed within the typical 15 days allotted and said the agency should instead focus on the adequacy of the establishment's response.
Hyman, Phelps & McNamara raised several other issues in its comments, including concerns that the signature requirement in the guidance may be administratively burdensome and irrelevant, and requiring certain consultant information may make it harder for establishments to find qualified support.
